|
C2ORF67 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.86009993466507E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.48479999961815E-07 |
| Normal-vs-Stage2 |
1.53999999996657E-06 |
| Normal-vs-Stage3 |
3.12850001460419E-09 |
| Normal-vs-Stage4 |
2.70869999985379E-07 |
| Stage1-vs-Stage2 |
1.216240E-01 |
| Stage1-vs-Stage3 |
1.976090E-02 |
| Stage1-vs-Stage4 |
6.404000E-02 |
| Stage2-vs-Stage3 |
8.678000E-01 |
| Stage2-vs-Stage4 |
8.349600E-01 |
| Stage3-vs-Stage4 |
9.481800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.43840003744111E-09 |
| Normal-vs-AfricanAmerican |
2.227900E-02 |
| Normal-vs-Asian |
1.210620E-04 |
| Caucasian-vs-AfricanAmerican |
1.979960E-01 |
| Caucasian-vs-Asian |
3.336200E-01 |
| AfricanAmerican-vs-Asian |
5.072600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.67070000004033E-07 |
| Normal-vs-Female |
5.82830006479185E-10 |
| Male-vs-Female |
7.032600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.61939999999894E-05 |
| Normal-vs-Age(41-60Yrs) |
2.2649000008812E-08 |
| Normal-vs-Age(61-80Yrs) |
9.43870004377345E-09 |
| Normal-vs-Age(81-100Yrs) |
1.0548999995752E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.629000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.220350E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.744720E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.923390E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.638900E-03 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.797700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.719900E-03 |
| Classical-VS-Follicular |
3.917800E-03 |
| Classical-VS-Other |
4.057800E-01 |
| Classical-VS-Normal |
3.92500000000462E-05 |
| Tall-VS-Follicular |
7.026800E-01 |
| Tall-VS-Other |
2.801900E-02 |
| Tall-VS-Normal |
9.45460000290055E-08 |
| Follicular-VS-Other |
9.776200E-02 |
| Follicular-VS-Normal |
1.2627000001153E-08 |
| Other-VS-Normal |
2.857600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.51910040102621E-10 |
| Normal-vs-N1 |
1.179040E-03 |
| N0-vs-N1 |
1.561760E-01 |
|
|
